- Stocks
- Pharma & Healthcare
- Shukra Pharma
Shukra Pharma share price
NSE: SHUKRAPHARPharma & HealthcareDrug Manufacturers - Specialty & Generic
Shukra Pharma at a glance
Shukra Pharma (NSE: SHUKRAPHAR) closed at ₹63.62 on 22 Oct 2026, down 7.18% on the day. With a market capitalisation of ₹2,797 Cr, it ranks 999th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 127.2× trailing earnings, against a return on equity of 15.2% in FY25. Its 52-week range is ₹40.06 (14 Aug 2026) to ₹75.40 (6 Oct 2026); the last close is 15.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹6 Cr (−52.4% year on year) and net profit −₹2 Cr (−131.9%), on a consolidated basis. Promoters held 51.15% of the company as of 3 Aug 2026.
Key numbers
- Market cap
- ₹2,797 CrRank 999 on NSE
- P/E (trailing)
- 127.2×
- Price to book
- 15.23×FY25
- EPS (TTM)
- ₹0.50to Q4 FY26
- ROE
- 15.2%FY25
- ROCE
- 20.0%FY25
- Debt to equity
- 0.07FY25
- Net profit margin
- 29.4%FY25
- Book value / share
- ₹1.44FY25
- 52-week high
- ₹75.406 Oct 2026
- 52-week low
- ₹40.0614 Aug 2026
- RSI (14-day)
- 53.4
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −7.18% | −5.0% | +14.8% | — | — |
Shukra Pharma quarterly results
| Quarter | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹11 Cr | ₹13 Cr | ₹5 Cr | ₹6 Cr | ₹39 Cr | ₹6 Cr |
| Revenue YoY | — | — | — | — | +269.8% | −52.4% |
| Net profit | ₹3 Cr | ₹5 Cr | ₹1 Cr | ₹2 Cr | ₹20 Cr | −₹2 Cr |
| Net profit YoY | — | — | — | — | +544.3% | −131.9% |
| Net margin | 29.9% | 40.6% | 19.1% | 40.5% | 52.0% | −27.2% |
| EPS | ₹0.72 | ₹0.12 | ₹0.02 | ₹0.05 | ₹0.47 | −₹0.04 |
Shukra Pharma financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹12 Cr | ₹11 Cr | ₹20 Cr | ₹59 Cr | ₹75 Cr | ₹33 Cr |
| Operating profit | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹4 Cr | ₹20 Cr | ₹13 Cr |
| Net profit | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹4 Cr | ₹19 Cr | ₹10 Cr |
| EPS (₹) | ₹0.23 | ₹0.22 | ₹4.79 | ₹26.21 | ₹16.93 | ₹0.22 |
| Cash from operations | ₹1 Cr | ₹0 Cr | ₹8 Cr | ₹3 Cr | −₹5 Cr | ₹8 Cr |
| Total debt | ₹8 Cr | ₹10 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr |
| Shareholders' equity | ₹15 Cr | ₹16 Cr | ₹16 Cr | ₹25 Cr | ₹58 Cr | ₹63 Cr |
Shukra Pharma shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 | 3 Aug 2026 |
|---|---|---|---|---|---|---|
| Promoters | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% | 51.15% |
| Foreign institutions | — | — | — | — | 0.00% | 0.00% |
| Domestic institutions | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% |
| Non-institutions | 48.93% | 48.93% | 48.93% | 48.93% | 48.92% | 48.73% |
Shukra Pharma vs peers
The listed Pharma & Healthcare companies nearest to Shukra Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SOLARASolara Active Pharma Sciences | ₹650.75 | +1.48% | +11.8% | ₹3,140 Cr | — | — |
| INDSWFTLABInd-Swift Laboratories | ₹347.05 | +1.92% | +240.9% | ₹3,018 Cr | 71.6 | — |
| ADVENZYMESAdvanced Enzyme Technologies | ₹265.45 | +1.39% | −13.2% | ₹2,972 Cr | 17.6 | — |
| SHUKRAPHARShukra Pharma | ₹63.62 | −7.18% | — | ₹2,797 Cr | 127.2 | — |
| DPC02Dishman Pharma | — | — | — | ₹2,676 Cr | — | — |
| HIKALHikal | ₹210.01 | −0.52% | −11.8% | ₹2,589 Cr | — | — |
| DRAGARWQDr Agarwals Eye Hospital | ₹5,025.00 | +0.12% | — | ₹2,428 Cr | — | — |
Ask anything about Shukra Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against SHUKRAPHAR's own history. Try: “Why has SHUKRAPHAR moved over the last three months?” · “Backtest a 50-day moving-average crossover on SHUKRAPHAR over five years” · “Compare SHUKRAPHAR with SOLARA on margins and valuation”
Frequently asked questions about Shukra Pharma
What is the share price of Shukra Pharma today?
Shukra Pharma (NSE: SHUKRAPHAR) last closed at ₹63.62 on 22 Oct 2026. Its 52-week high is ₹75.40 and its 52-week low is ₹40.06.
What is the market cap of Shukra Pharma?
Shukra Pharma's market capitalisation is ₹2,797 Cr (₹2,797 Cr) at the 22 Oct 2026 close, ranking 999th among the NSE companies Pivot tracks.
What is the P/E ratio of Shukra Pharma?
Shukra Pharma trades at a trailing P/E of 127.2.
What is the ROE and ROCE of Shukra Pharma?
Return on equity was 15.2% in FY25 and return on capital employed was 20.0% in FY25 (standalone figures).
Is Shukra Pharma a debt-free company?
No. Shukra Pharma's debt-to-equity ratio was 0.07 in FY25, with total debt of ₹3 Cr.
What were Shukra Pharma's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Shukra Pharma reported revenue of ₹6 Cr, −52.4% year on year, and net profit of −₹2 Cr, −131.9% year on year.
What is the shareholding pattern of Shukra Pharma?
As of 3 Aug 2026: promoters 51.15%, foreign institutions 0.00%, domestic institutions 0.11%, non-institutions 48.73%.
Who are Shukra Pharma's competitors?
The listed Pharma & Healthcare companies closest to Shukra Pharma by market cap are Solara Active Pharma Sciences, Ind-Swift Laboratories, Advanced Enzyme Technologies, Dishman Pharma, Hikal and Dr Agarwals Eye Hospital.
Is Shukra Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Shukra Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SHUKRAPHAR against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text